http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
이호진 ( Ho Jin Lee ),남승범 ( Seung Bum Nam ),정재욱 ( Jae Wook Jung ),나임일 ( Im Il Na ),김철현 ( Cheol Hyeon Kim ),류백렬 ( Baek Yeol Ryoo ),최두환 ( Du Whan Choe ),강진형 ( Jin Hyung Kang ),이재철 ( Jae Cheol Lee ) 대한결핵 및 호흡기학회 2007 Tuberculosis and Respiratory Diseases Vol.62 No.2
Gefitinib is a novel drug used to treat advanced non-small cell lung cancer. However, drug-related interstitial pneumonia is a major life-threatening side effect, which has a worldwide prevalence of 0.3-0.4%. In Japan, the prevalence is high as 3-4% but the actual frequency in Korea has not been officially assessed. We report two cases of gefitinib-induced interstitial lung disease during the treatment of non-small cell lung cancer. High-resolution computerized tomography (HRCT) of one case showed nonspecific ground glass opacity and the chest x-ray of another case showed diffuse bilateral ground glass opacity. The former patient showed a rapid good response to corticosteroid treatment whereas the latter died despite receiving aggressive treatment with high dose corticosteroid and empirical antibiotics. (Tuberc Respir Dis 2007; 62: 134-139)
김태용(Tae Yong Kim),조요한(Yo Han Joh),김진수(Jin Su Kim),홍용상(Yong Sang Hong),이근욱(Keun Wook Lee),윤탁(Tak Yun),송은기(Eun Ki Song),나임일(Im Il Na),신현춘(Hyun Chun Shin),김동완(Dong Wan Kim),이재서(Chae Seo RLee),성명훈(Myung W 대한두경부종양학회 2004 대한두경부 종양학회지 Vol.20 No.2
Background: About 3% of all cancer patients suffer from cancer of unknown primary origin. Generally, carcinoma of unknown primary (CUP) carries a grave prognosis, but primary tumor presented to the neck is exception to this. The aims of study are to determine the role of chemotherapy and to find the prognostic factors in unknown primary tumor presented to the neck. Method and Material: Eighty-four patients were diagnosed with unknown primary tumor presented to the neck between January 1996 and June 2002. Among 84 patients, 43 patients (52%) received chemotherapy, radiation or surgery were performed in 20 patients (23%), 21 patients (25%) had no treatment. Results: The response rates to chemotherapy were 87.5% in CUP only localized to the neck and 44.0% in CUP systemically involved (p=0.012). A median follow-up duration was 6.4 years and overall median survival time was 9 months. The median overall survival time of patients treated with chemotherapy were 17 months and that of patients who received surgery or radiation were 20 months (p=0.3548). The important prognostic factors were performance status and the number of involved organ. Conclusion: The prognosis of patients with CUP presented to the neck is more favorable than that of patients with CUP of other localization. The effectiveness of chemotherapy for CUP only localized to the neck was similar to that of surgery or radiation. The important prognostic factors were performance status and the number of involved organ.
김지현,허대석,이세훈,이원섭,김노경,김학균,방수미,변재호,류민희,이근석,정주영,나임일,방영주 대한내과학회 2000 대한내과학회지 Vol.58 No.4
Background : The aim of this study is to determine prognostic factors of breast cancer in Korean patients who underwent curative mastectomy. Methods : Medical records of 181 patients who underwent curative mastectomy were reviewed. Relapse-free survival and overall survival were documented for each patient. Factors influencing survival were analyzed using Cox proportional hazard model. Results : Overall 5-year survival rate was 82.0%, and 8-year survival rate was 74.7%. Multivariate analysis indicated that multiple axillary lymph node involvement (≥4), postmenopausal status, and negative estrogen receptor were independent adverse prognostic factors. The adjusted relative risks of multiple axillary lymph node involvement (≥4), postmenopausal status, and negative estrogen receptor were estimated 2.60 (95% Confidence Interval (CI): 1.28-5.30), 2.64 (95% CI: 1.46-4.79), and 2.27 (95% CI: 1.19-4.35), respectively. Conclusion : Multiple axillary lymph node involvement (≥4), postmenopausal status, and negativstrogen receptor were independent adverse prognostic factors in Korean breast cancer patients after curative mastectomy.(Korean J Med 58:446-452, 2000)$quot;